索拉非尼
肝细胞癌
医学
血管生成
癌症研究
背景(考古学)
酪氨酸激酶
酪氨酸激酶抑制剂
抗药性
自噬
上皮-间质转换
癌症
肿瘤科
内科学
细胞凋亡
生物
转移
受体
古生物学
生物化学
微生物学
作者
Yongchao Tian,Lei Yuan,Yuna Fu,Hao Sun,Jianhua Wang,Feng Xia
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2022-07-01
卷期号:22 (6): 454-462
被引量:7
标识
DOI:10.2174/1568009622666220330151725
摘要
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death, which can be attributed to the high incidence and first diagnosis at an advanced stage. Tyrosine kinase inhibitors (TKIs), a class of small-molecule targeting drugs, are primarily used for the clinical treatment of HCC after chemotherapy because they show significant clinical efficacy and low incidence of clinical adverse reactions. However, resistance to sorafenib and other TKIs, which can be used to treat advanced HCC, poses a significant challenge. Recent mechanistic studies have shown that epithelial-mesenchymal transition or transformation (EMT), ATP binding cassette (ABC) transporters, hypoxia, autophagy, and angiogenesis are involved in apoptosis, angiogenesis, HCC cell proliferation, and TKI resistance in patients with HCC. Exploring and overcoming such resistance mechanisms is essential to extend the therapeutic benefits of TKIs to patients with TKI-resistant HCC. This review aims to summarize the potential resistance mechanism proposed in recent years and methods to reverse TKI resistance in the context of HCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI